– Second Quarter 2023 Total Revenue of $38.3 Million; Net Product Revenue for QINLOCK® (ripretinib) Increased 18% to $37.3 Million Compared to Second Quarter 2022 –– Top-line Results for MOTION Pivotal Phase 3 Study of Vimseltinib Expected in Fourth Quarter 2023 –– INSIGHT Pivotal Phase 3 Study of QINLOCK in Second-.
– First Quarter 2023 Total Revenue of $33.4 Million; Net Product Revenue for QINLOCK® Increased 15% to $33.2 Million Compared to First Quarter 2022 –
– Enrollment Complete in. | May 3, 2023